ArticleParasite (Paris, France)2016
In vitro inhibitory effects of plant-derived by-products against Cryptosporidium parvum.
Article in Parasite (Paris, France), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Phytoextracts Used in the Treatment of Cryptosporidiosis and Giardiasis: Current State.Acta parasitologica · 2026Review
- Potential Application of Plant By-Products in Biomedicine: From Current Knowledge to Future Opportunities.Antioxidants (Basel, Switzerland) · 2025Review
- Efficacy of medicinal plants in cryptosporidiosis treatment: a comprehensive review.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Review
- Polyphenolic Profile ofPharmaceutics · 2023Article
- Use of agro-industrial by-products containing tannins for the integrated control of gastrointestinal nematodes in ruminants.Parasite (Paris, France) · 2022Review
- Extracts of pine bark (Pinus sylvestris) inhibit Cryptosporidium parvum growth in cell culture.Parasitology research · 2021Article
- Anti-protozoal activity of extracts from chicory (Cichorium intybus) against Cryptosporidium parvum in cell culture.Scientific reports · 2019Article
- Discovery of Novel Anti-cryptosporidial Activities From Natural Products byFrontiers in microbiology · 2019Article
- A Novel Natural Antimicrobial Can Reduce theFrontiers in microbiology · 2018Article
- The in vitro and ex vivo effect of Auranta 3001 in preventingGut pathogens · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disposal of organic plant wastes and by-products from the food or pharmaceutical industries usually involves high costs. In the present study, 42 samples derived from such by-products were screened in vitro against Cryptosporidium parvum, a protozoan parasite that may contaminate drinking water and cause diarrhoea. The novel bioassay was previously established in the microtitre plate format. Human ileocaecal adenocarcinoma (HCT-8) cell cultures were seeded with C. parvum oocysts and parasite development was monitored by an indirect fluorescent antibody technique (IFAT) and microscopic assessment for clusters of secondary infection (CSI). Minimum inhibitory concentrations (MICs) and potential detrimental effects on the host cells were determined. An ethanolic extract from olive (Olea europaea) pomace, after oil pressing and phenol recovery, reproducibly inhibited C. parvum development (MIC = 250-500 μg mL(-1), IC50 = 361 (279-438) μg mL(-1), IC90 = 467 (398-615) μg mL(-1)). Accordingly, tyrosol, hydroxytyrosol, trans-coniferyl alcohol and oleuropein were selected as reference test compounds, but their contributions to the observed activity of the olive pomace extract were insignificant. The established test system proved to be a fast and efficient assay for identifying anti-cryptosporidial activities in biological waste material and comparison with selected reference compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.